Sorafenib tosylate

Quick Details:

Product Name: Sorafenib tosylate

Chemical name/Alias: Sorafenib Free Base;Forafenib

CAS NO: 284461-73-0

Appearance: white powder

MF: C21H16ClF3N4O3

Purity: 99%

Origin: China

Export market: Global

Grade: Pharmaceutical grade

Supply capacity: Mass in stock.

Usage: inhibitors

Description:

Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.

Mechanism of action

Sorafenib is a small inhibitor of several tyrosine protein kinases, such as VEGFR, PDGFR and Raf family kinases (more avidly C-Raf than B-Raf).

Sorafenib treatment induces autophagy, which may suppress tumor growth. However, autophagy can also cause drug resistance.

Medical uses

At the current time sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thyroid cancer.

Kidney cancer

Clinical trial results, published January 2007, showed that, compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear cell renal cell carcinoma in whom previous therapy has failed. The median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group.